Elena Pezzolo1, Unal Mutlu2, Meike W Vernooij3, Emmilia A Dowlatshahi4, Paolo Gisondi5, Giampiero Girolomoni5, Tamar Nijsten4, M Arfan Ikram6, Marlies Wakkee7. 1. Department of Dermatology, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands; Department of Medicine, Section of Dermatology and Venerology, University of Verona, Verona, Italy. 2. Department of Epidemiology, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands; Department of Ophthalmology, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands. 3. Department of Epidemiology, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands. 4. Department of Dermatology, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands. 5. Department of Medicine, Section of Dermatology and Venerology, University of Verona, Verona, Italy. 6. Department of Epidemiology, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands. 7. Department of Dermatology, Erasmus Medical Center University Medical Center, Rotterdam, the Netherlands. Electronic address: m.wakkee@erasmusmc.nl.
Abstract
BACKGROUND: Based on increased cardiometabolic comorbidities, inflammation, and an overlap in genetics with Alzheimer disease, psoriasis patients might be at risk for cognitive dysfunction and dementia. OBJECTIVE: To compare cognition, magnetic resonance imaging (MRI)-markers, and dementia risk in psoriasis and nonpsoriasis participants in the population-based Rotterdam Study. METHODS: We identified 318 psoriasis and 9678 nonpsoriasis participants (mean age 66.1 years, 58% women). The association of psoriasis with cognitive function, mild cognitive impairment, and MRI-markers of brain damage was examined by linear and logistic regression. Dementia risk was calculated using Cox regression. Models were adjusted for age, sex, education, and cardiovascular risk factors. RESULTS: Cognitive test scores and volumetric, microstructural, focal measures on brain MRI did not differ between psoriasis (28% systemic and ultraviolet treatment) and nonpsoriasis participants, and psoriasis was not associated with mild cognitive impairment (adjusted odd ratio 0.87, 95% confidence interval 0.53-1.43). During 115.000 person-years of follow-up, 810 incident dementia cases (15 among psoriasis patients) occurred. After adjusting for confounders, psoriasis was associated with a lower risk of developing dementia (adjusted hazard ratio 0.50, 95% confidence interval 0.28-0.91). LIMITATIONS: Limited dementia cases among psoriasis patients. CONCLUSION: In this population-based study, psoriasis was not associated with preclinical markers or higher dementia risk.
BACKGROUND: Based on increased cardiometabolic comorbidities, inflammation, and an overlap in genetics with Alzheimer disease, psoriasis patients might be at risk for cognitive dysfunction and dementia. OBJECTIVE: To compare cognition, magnetic resonance imaging (MRI)-markers, and dementia risk in psoriasis and nonpsoriasis participants in the population-based Rotterdam Study. METHODS: We identified 318 psoriasis and 9678 nonpsoriasis participants (mean age 66.1 years, 58% women). The association of psoriasis with cognitive function, mild cognitive impairment, and MRI-markers of brain damage was examined by linear and logistic regression. Dementia risk was calculated using Cox regression. Models were adjusted for age, sex, education, and cardiovascular risk factors. RESULTS: Cognitive test scores and volumetric, microstructural, focal measures on brain MRI did not differ between psoriasis (28% systemic and ultraviolet treatment) and nonpsoriasis participants, and psoriasis was not associated with mild cognitive impairment (adjusted odd ratio 0.87, 95% confidence interval 0.53-1.43). During 115.000 person-years of follow-up, 810 incident dementia cases (15 among psoriasis patients) occurred. After adjusting for confounders, psoriasis was associated with a lower risk of developing dementia (adjusted hazard ratio 0.50, 95% confidence interval 0.28-0.91). LIMITATIONS: Limited dementia cases among psoriasis patients. CONCLUSION: In this population-based study, psoriasis was not associated with preclinical markers or higher dementia risk.
Authors: Luiza Marek-Jozefowicz; Adam Lemanowicz; Małgorzata Grochocka; Monika Wróblewska; Katarzyna Białczyk; Katarzyna Piec; Grzegorz M Kozera; Zbigniew Serafin; Rafał Czajkowski; Alina Borkowska Journal: Int J Environ Res Public Health Date: 2022-05-07 Impact factor: 4.614
Authors: Giovanni Damiani; Joselin D Tacastacas; Timothy Wuerz; Lindsay Miller; Philip Fastenau; Christopher Bailey; Mansi Sethi Chawa; Amanda Argenas; Marco Fiore; Kevin D Cooper; Alan J Lerner Journal: Biomed Res Int Date: 2022-07-21 Impact factor: 3.246